Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA Compliance for Peptide Therapy and BPC 157 Holt Law On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval. FDA's Formal Position on Enforcement Discretion Revealed Vapor Technology Association Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences Is BPC 157 Banned? Oral vs. Injectable Forms Explained